Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase - PubMed
- ️Wed Jan 01 1997
. 1997 Nov 1;57(21):4838-48.
E G Barbacci, K K Iwata, L Arnold, B Boman, A Cunningham, C DiOrio, J Doty, M J Morin, M P Moyer, M Neveu, V A Pollack, L R Pustilnik, M M Reynolds, D Sloan, A Theleman, P Miller
Affiliations
- PMID: 9354447
Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase
J D Moyer et al. Cancer Res. 1997.
Abstract
The epidermal growth factor receptor (EGFR) is overexpressed in a significant percentage of carcinomas and contributes to the malignant phenotype. CP-358,774 is a directly acting inhibitor of human EGFR tyrosine kinase with an IC50 of 2 nM and reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM. This inhibition is selective for EGFR tyrosine kinase relative to other tyrosine kinases we have examined, both in assays of isolated kinases and whole cells. At doses of 100 mg/kg, CP-358,774 completely prevents EGF-induced autophosphorylation of EGFR in human HN5 tumors growing as xenografts in athymic mice and of the hepatic EGFR of the treated mice. CP-358,774 inhibits the proliferation of DiFi human colon tumor cells at submicromolar concentrations in cell culture and blocks cell cycle progression at the G1 phase. This inhibitor produces a marked accumulation of retinoblastoma protein in its underphosphorylated form and accumulation of p27KIP1 in DiFi cells, which may contribute to the cell cycle block. Inhibition of the EGFR also triggers apoptosis in these cells as determined by formation of DNA fragments and other criteria. These results indicate that CP-358,774 has potential for the treatment of tumors that are dependent on the EGFR pathway for proliferation or survival.
Similar articles
-
Lee LT, Huang YT, Hwang JJ, Lee PP, Ke FC, Nair MP, Kanadaswam C, Lee MT. Lee LT, et al. Anticancer Res. 2002 May-Jun;22(3):1615-27. Anticancer Res. 2002. PMID: 12168845
-
Ahmad N, Gali H, Javed S, Agarwal R. Ahmad N, et al. Biochem Biophys Res Commun. 1998 Jun 18;247(2):294-301. doi: 10.1006/bbrc.1998.8748. Biochem Biophys Res Commun. 1998. PMID: 9642119
-
Liu Y, Poon RT, Shao W, Sun X, Chen H, Kok TW, Fan ST. Liu Y, et al. Cancer Lett. 2007 Apr 8;248(1):32-40. doi: 10.1016/j.canlet.2006.05.018. Epub 2006 Jul 11. Cancer Lett. 2007. PMID: 16837130
-
Foon KA, Yang XD, Weiner LM, Belldegrun AS, Figlin RA, Crawford J, Rowinsky EK, Dutcher JP, Vogelzang NJ, Gollub J, Thompson JA, Schwartz G, Bukowski RM, Roskos LK, Schwab GM. Foon KA, et al. Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):984-90. doi: 10.1016/j.ijrobp.2003.09.098. Int J Radiat Oncol Biol Phys. 2004. PMID: 14967460 Review.
-
Immunohistochemical determination of EGFR-tyrosine kinase inhibition in clinical samples.
Malik SN, Bedolla RG, Hidalgo M, Brattain MG, Kreisberg JI. Malik SN, et al. Methods Mol Med. 2003;85:135-40. doi: 10.1385/1-59259-380-1:135. Methods Mol Med. 2003. PMID: 12710204 Review. No abstract available.
Cited by
-
Zou Y, Ling YH, Sironi J, Schwartz EL, Perez-Soler R, Piperdi B. Zou Y, et al. J Thorac Oncol. 2013 Jun;8(6):693-702. doi: 10.1097/JTO.0b013e31828c7210. J Thorac Oncol. 2013. PMID: 23575415 Free PMC article.
-
TSLP signaling network revealed by SILAC-based phosphoproteomics.
Zhong J, Kim MS, Chaerkady R, Wu X, Huang TC, Getnet D, Mitchell CJ, Palapetta SM, Sharma J, O'Meally RN, Cole RN, Yoda A, Moritz A, Loriaux MM, Rush J, Weinstock DM, Tyner JW, Pandey A. Zhong J, et al. Mol Cell Proteomics. 2012 Jun;11(6):M112.017764. doi: 10.1074/mcp.M112.017764. Epub 2012 Feb 16. Mol Cell Proteomics. 2012. PMID: 22345495 Free PMC article.
-
Vicentini C, Festuccia C, Gravina GL, Angelucci A, Marronaro A, Bologna M. Vicentini C, et al. J Cancer Res Clin Oncol. 2003 Mar;129(3):165-74. doi: 10.1007/s00432-003-0420-3. Epub 2003 Mar 4. J Cancer Res Clin Oncol. 2003. PMID: 12712332
-
Quintela-Fandino M, Le Tourneau C, Duran I, Chen EX, Wang L, Tsao M, Bandarchi-Chamkhaleh B, Pham NA, Do T, MacLean M, Nayyar R, Tusche MW, Metser U, Wright JJ, Mak TW, Siu LL. Quintela-Fandino M, et al. Mol Cancer Ther. 2010 Mar;9(3):751-60. doi: 10.1158/1535-7163.MCT-09-0868. Epub 2010 Mar 2. Mol Cancer Ther. 2010. PMID: 20197396 Free PMC article. Clinical Trial.
-
Targeting the function of the HER2 oncogene in human cancer therapeutics.
Moasser MM. Moasser MM. Oncogene. 2007 Oct 11;26(46):6577-92. doi: 10.1038/sj.onc.1210478. Epub 2007 May 7. Oncogene. 2007. PMID: 17486079 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous